




ArcaScience

# Anticipating Drugs' Success from Day 1

The first AI-powered solution  
**modeling drugs' benefits & risks**






## Facts & Issues

- +10 years to bring a drug to market
- Fails 9/10 times & costs an average of \$2.3B per drug
- Reasons:
  - Lack of efficacy 57%
  - Safety issues 17%

Sources: Annexes

# The benefit-risk assessment market: \$13.2 billion per year, currently served only by lagging service companies




With an **unlimited** delivery capability unlocked in 2026, ArcaScience is posed to become the new standard for benefit-risk analysis, both for industrials and regulators\*\*

## Yearly Market Distribution



# Our Mission

Revolutionizing the Benefit Risk Evaluation  
& Becoming the World Leader of the Field  
by replacing the service-companies on  
this \$13B\* market



# One Benefit-Risk Environment Across...



Improve clinical pipeline  
by anticipating benefits and  
potential applications



Master drugs' impact for every  
patient



AstraZeneca



All insight generated based on a personally selected set of sources

Clients' private databases

AS Profiling Base 100B<sup>®1</sup>

Subscription databases

# ArcaScience Dramatically Changes the Way These Evaluations are Conducted

## Build your drug's BRE in seconds

*Don't spend months looking for it*

By far the most  
comprehensive BRE  
database in the world



24 small AI models  
trained by clinicians

*unmatched, with over 100B data points*

...



## Delivered on a regulator-validated, dashboarded solution

Benefits & Risks  
Strengths, weaknesses  
& opportunities



Approval Optimization  
*Risk mitigation, new design  
amendment strategies,  
better applications*

# The First Prospective Benefit-Risk Solution

## with a Customised Dashboard to Build your Analyses

**Good morning, Dr. Clément**

Here's your overview of active benefit-risk analyses

**2**  
ACTIVE PROJECTS

**0**  
COMPLETED THIS MONTH

**Active Projects** + Create Project View All Projects →

**PROJECT-115 | PRJ-DAB-AF**  
Outcomes Identification (Step 2)

Due: 15/03/2026 Progress: 38%  

**Continue Analysis →**

**PROJECT-088 | PRJ-SEC-HS NEW**  
Delivery (Step 7)

Due: 05/02/2025 Progress: 100%  

**Update Available**

Recent Publications Priority Alerts

Back to Projects PROJECT-088 Active Adalimumab vs Secukinumab in Hidradenitis Suppurativa Workflow Progress 100%

BRAT WORKFLOW

- Step 0: Configuration
- Step 1: Context
- Step 2: Outcomes Identification
- Step 3: Data Analysis
- Step 4: Customize**
- Step 5: Weighting
- Step 6: Display

**Customize Value Tree** Edit categories, weights, and structure of your value tree

**Value Tree Structure** Filter by tags: FDA-Approved Endpoint, EMA-Accepted Endpoint, Primary Endpoint, Frequently Used, MCID Available, Early Endpoint, Clinician-Assessed, Composite Outcome

**Visual Tree Preview** The value tree shows the hierarchical structure of benefits and risks with their relative

Reduce BRA Project Time by 80%<sup>1</sup>

<sup>1</sup>: independent BRA expert evaluations, 2025

# R&D Impact Proven



*"As a Global R&D, I want to predict benefit-risk of my drug  
from the preclinical stage down to the market  
authorization (10 years)"*

Benefit Risk Anticipation  
in 2023

sanofi

# Results

For the 1st time in Sanofi's history:

successfully achieved a benefit-risk prediction based on 9 times more insights coming from internal & external sources



**Millions re-routed** thanks to the anticipated assessment of thromboembolic risks

**18 months of work** done in mere seconds

**ArcaScience = \$100K      Vs.      CRO = \$1.2M**

# Track Record

Total amount raised

**\$10M**

Last fundraising : **\$7M**  
in September 2025

Awarded best healthtech NLP  
Startup 2023<sup>1</sup>

**20+** blue chip clients running our solution

## Some major achievements clients and partners



Benefit-risk evaluation time : **-60%**



BR evaluation cost : **-70%**



Risks modeling (200+/y) : **instant**



Benefits modeling insights : **+30%**



Drug-Drug Interaction modeling:  
**X3 the amount DDIs detected**

# Time for AI Solutions!

8/10 1st meetings lead to a deal

Company	 ArcaScience	causaly	ProQuest	nference®	 IQVIA™
Comprehensive data access	✓	✗	✓	✓	✗
High frequency data profiling	✓	✗	✗	✗	✓
AI-expert	✓	✓	✗	✓	✓
Automated benefit-risk analysis	✓	✗	✗	✗	✗
Service-based	✗	✓ ✗	✓	✗	✓



ArcaScience secured 100% of its deals facing consulting companies

"By 2026 80% of pharma will have adopted AI benefit-risk enabled solutions" - IDC Top 10 Predictions for 2025



ArcaScience

# A Highly Qualified Team

Where AI research meets  
drug impact

# 14FTEs, 20 Collaborators Total



**Romain Clement**  
CEO & Co-Founder

Scientific data management expert, Lead  
**GSK** clinical data management



**Jean-François Arbona**  
CTO

25 years as a CTO and developer  
Serial entrepreneur and investor



**Carlo Petruzzielo**  
Head of Sales - USA

20 years head of sales  
Scaled 4 startups prior to ArcaScience



**Vassili Soumelis, MD, PhD**  
Chief Medical Officer

Former CMO Owkin (unicorn) 2025  
Immunologist & AI expert



**Charbel Alhelou, PhD**  
Head of Product

Biomedical & pharmaceutical market  
expert



**Patrick Pierre**  
IT Lead & Co-Founder

Sales entrepreneur,  
Computer Science Engineer



**Praise Oketola**  
AI Engineer

AI Engineer,  
LLM Developer



**Ons Arouri**  
MLOps

Biotech Engineer NLP-NER specialist  
Biomedical Data Scientist



**Natalia Bobkova**  
ML Engineer

AI Engineer,  
LLM Developer in healthcare

# Our Scientific Committee ~25% Equity









 Paris Brain Institute  
Institut de France Académie des sciences









Laurent Romary, PhD

**Head of AI department, INRIA,**  
President of DARIAH

Philippe Peyre

Senior VP, **General Secretary**  
Sanofi

Pr. Alexis Brice

**Founder & President, Brain Institute of Paris**, Neurologist, member of the French Academy of Sciences

Kerry Coffee

Founding Principal, Schiller Discovery Healthtech Venture, BioVenture eLab

Jean Lopategui

Professor of Pathology  
Hematopathologist &  
Molecular Pathologist













 G

Emmanuel Capitaine, PhD

International Medical coordinator, Vivalto.  
Previously : Head Innovation,  
AstraZeneca

Serge Bauin, PhD

Managing Director STI CNRS,  
French Minister's Head Data Science Expert

Geneviève Laurans

Administrator & CFO, Quotium Technologies. Labour Court Judge, Paris

Pr. Clemens M. Schirmer

**Neurosurgeon**, Professor, Vice Chair and program director, Geisinger hospital & School of Medicine

# Scaling Across the Industry

\$1M already signed for 2026





Romain CLEMENT  
CEO & Co-Founder

✉ roman@arcascience.ai  
📞 +336.38.56.15.21  
🌐 www.arcascience.ai

Future 4 Care, Biopark, 75013, PARIS

# Thank you!

Trusted by



# Six Pre-Configured Output Study Types

## Analysis of Condition



### Disease Analysis

Discover molecular pathways and epidemiological information about your disease

## Current Treatments



### Clinical Landscape + Efficacy Report

Access to a global synthesis of clinical activities with sponsors, treatments...

## Benefits



### Clinical Endpoint Study

Access to an accurate analysis of all clinical endpoint strategy for a pathology

## Risks



### Adverse Events Reports

Get a synthesis of all adverse events related to your drug and the standard of care

## Benefit-Risk Assessment



### Benefit Risk Assessment

Access to a summarized BRA regarding your priorities

## Conclusion



### Benefit Risk Summary

Review a synthesis of your tailored Benefit-Risk Analysis

Each Study Delivers Full Data Transparency and FDA-Compliant Documentation

# Exit Landscape

	Example	Deals Made	Time Frame	Amount
Pharma Companies	Roche AstraZeneca	 for \$100M  for \$85M	Earliest: 2026/2027	2027: 100M/200M
CROs	ICON MRT	 for \$1.2B by Clarivate	Earliest: 2025	2025: 20M/30M 2026: 100M/200M
AI Pharma Provider	Vidal	 for \$525M by Optum	Earliest: 2026/2027	2027: 100M/200M
Private Equity	Eurazeo Andera Partners	 for \$325M by GTCR	Earliest: 2026/2027	2027: 100M/200M

# The Benefit-Risk Assessment Market: \$13.2 Billion per Year, Currently Only Served by Lagging Service Companies

Drug Development Phase	Market Size per Phase	Number of Drugs in Phase
Lead Candidates	0	283 775
Preclinical Phase	\$1.15B	11 351
Phase 1	\$1.47B	2 947
Phase 2	\$1.39B	1 385
Phase 3	\$0.39B	388
Submission	\$0.32B	213
Post-Marketing	\$8.4B	196

# In-Depth Major Piece of Pipeline Review

April 2025

Deals	Offer	Amount	Closing	Comment
Sanofi Vaccines	BRA	250K €	Q2 <small>budgets approved</small>	Holistic vaccine use extension detection (E.M. BRA AI)
Biocodex	BRA	100K €	Q1	First contract follow-up E.M. BRA AI
Vidal Extension	DDI	200K €	Q1 <small>budgets approved</small>	First contract follow-up E.M. BRA AI
Sanofi - BRA	BRA	450K €	Q2	New E.M. BRA Slots
Dilon	LR project	40K €	Q2	Market extension discussion with FDA

Amounts are for first year contracts including renewal fees

# Product Market Expectations

## Exhaustive Coverage

Legal compliance needs

## Precision


Scientific needs

## Patient Focus

Business &  
marketing needs

These expectations drive all our product decisions & priorities

# A Unique Benefit-Risk Ensemble Model (E.M.): The Bedrock of Benefit-Risk Analysis



2024

First Corporate BRA  
First Medical Field Portal

2025

Corporate BRA Streamline  
3 New Medical Field Portals

2026

First Patient BRA Solution  
3 New Medical Fields  
First Corporate Patient-Level BRA

# 3 key cases of in-house attempts expected to be used for B-R Analysis



**Darwin Project**  
2019

Internal development, in  
collaboration with Aetion

Discontinued in 2021



**Voyager Project**  
2016

Internal development, in  
collaboration with IBM Watson

Discontinued in 2020



**Data42 Project**  
2020

Internal development

Discontinued in 2023

# The Sanofi Case

Portfolio depth of a Typical Client

Therapeutic area	Phase 1	Phase 2	Phase 3
Immunology & Inflammation	8	14	13
Neurology	1	4	2
Oncology	3	5	4
Rare Diseases	0	4	3
Vaccines	2	5	5

Total client market value : \$23.6M

# Appendices

- Citeline. (n.d.). *Why are clinical development success rates falling?* Retrieved from <https://www.citeline.com/en/resources/why-are-clinical-development-success-rates-falling>
- Informa Pharma Intelligence. (2022). *R&D Infographic 2022*. Retrieved from [https://images.intelligence.informa.com/Web/InformaUKLimited/%7B120ce195-3040-41d7-9b17-94c6aec9760f%7D\\_12647\\_Informa\\_R\\_D\\_Infographic\\_2022\\_8.pdf](https://images.intelligence.informa.com/Web/InformaUKLimited/%7B120ce195-3040-41d7-9b17-94c6aec9760f%7D_12647_Informa_R_D_Infographic_2022_8.pdf)
- Greenfield Chemical. (2023, August 10). *The Staggering Cost of Drug Development: A Look at the Numbers*. Retrieved from <https://greenfieldchemical.com/2023/08/10/the-staggering-cost-of-drug-development-a-look-at-the-numbers/#:~:text=Phase%20I%3A%20Approximately%20%2425%20million,expensive%2C%20averaging%20at%20%24350%20million.>
- EvaluatePharma. (n.d.). *World Preview Reports*. Often breaks down global R&D spending trends, forecasting total R&D to exceed \$250–285B by the mid-2020s.
  - *EvaluatePharma 2022 (Report Registration)*
- EFPIA (European Federation of Pharmaceutical Industries and Associations). (n.d.). *The Pharmaceutical Industry in Figures*. Overview of European/global R&D investment, though not typically broken down by phase. Retrieved from <https://www.efpia.eu>
- IQVIA. (n.d.). *Insights on Pharma R&D*. Provides high-level analyses of global spending, often citing \$200 B+ in annual pharmaceutical R&D. Retrieved from <https://www.iqvia.com/insights>
- PhRMA (Pharmaceutical Research and Manufacturers of America). (2022). *Industry Profile*. Focuses on R&D investments by PhRMA member companies in the U.S., surpassing \$100 B in 2021. Retrieved from <https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/0-9/2022-Industry-Profile.pdf>
- BIO / Informa Pharma Intelligence. (2021). Clinical Development Success Rates and Contributing Factors 2011–2020. While focused on success rates, they occasionally reference spending proportions at different phases. Retrieved from <https://www.bio.org/sites/default/files/2021-02/Clinical%20Development%20Success%20Rates%202011-2020%20-%20BIO%2C%20Informa%20Pharma%20Intelligence%20%26%20QLS.pdf>
- StartUs Insights. (n.d.). Top 9 Natural Language Processing Startups Impacting Industry 4.0. Retrieved from <https://www.startus-insights.com/innovators-guide/natural-language-processing-startups/>